Emergency Medicine Hub / Neurology & Psychiatry • 3 min read • 2 sections

Guillain-Barré Syndrome & Variants

Comprehensive emergency evaluation and protocolized management of Guillain-Barré Syndrome (GBS/Acute Inflammatory Demyelinating Polyradiculoneuropathy [AIDP]) and its clinical variants: molecular mimicry following Campylobacter jejuni, CMV, or Epstein-Barr infections; anti-ganglioside autoantibodies, symmetrical ascending flaccid paralysis with hyporeflexia/areflexia, the classic Miller Fisher syndrome triad (ataxia, areflexia, ophthalmoplegia with anti-GQ1b antibodies), diagnostic lumbar puncture (albuminocytologic dissociation: high CSF protein with normal WBC count), respiratory failure monitoring (the '20/30/40 rule' and forced vital capacity), immunotherapy (IVIG vs. plasma exchange), and absolute contraindications to succinylcholine and corticosteroids.

Resuscitation Quick Actions • First 2 Minutes

High-Acuity

The 20/30/40 Intubation Rule

FVC < 20 mL/kg, NIF less negative than -30 cmH2O, or MEP < 40 cmH2O = ELECTIVE ENDOTRACHEAL INTUBATION STAT

Succinylcholine LETHAL

STRICTLY CONTRAINDICATED: Denervation upregulates extrajunctional ACh receptors; succinylcholine causes massive fatal hyperkalemia

Albuminocytologic Dissociation

Lumbar puncture: Elevated CSF protein (> 45–100 mg/dL) with completely NORMAL CSF white blood cell count (< 5–10 cells/mcL)

Miller Fisher Triad

Ophthalmoplegia (extraocular muscle paralysis) + Ataxia + Areflexia; associated with anti-GQ1b ganglioside antibodies

Definitive Immunotherapy

IVIG 0.4 g/kg/day IV for 5 days OR Plasma Exchange (Plasmapheresis x 5 sessions); equal efficacy; DO NOT combine them

Steroids are Ineffective

Systemic corticosteroids (IV methylprednisolone) have been proven completely ineffective in GBS and should NOT be given

Bottom-Line Clinical Pearl

Guillain-Barré Syndrome (GBS) is an acute, post-infectious autoimmune polyradiculoneuropathy presenting with progressive, symmetrical, ascending flaccid paralysis and hyporeflexia/areflexia, typically beginning in the lower extremities 1–4 weeks after a gastroenteritis (Campylobacter jejuni) or respiratory illness. Sensation is relatively preserved compared to motor loss. The primary emergency threat is acute neuromuscular respiratory failure (intercostal and diaphragmatic paralysis, occurring in 20–30% of patients). Monitor respiratory mechanics serially using the '20/30/40 rule': Forced Vital Capacity (FVC) < 20 mL/kg, Negative Inspiratory Force (NIF) less negative than -30 cmH2O, or maximum expiratory pressure < 40 cmH2O MANDATES INTUBATION! Never use Succinylcholine for intubation (causes fatal hyperkalemic cardiac arrest due to denervation upregulation of nicotinic receptors). Treatment is IVIG (0.4 g/kg/day x 5 days) or Plasmapheresis; systemic steroids are COMPLETELY INEFFECTIVE.

1. Pathophysiology: Molecular Mimicry & Variants

Guillain-Barré Syndrome (GBS) is triggered by an antecedent infection—most commonly Campylobacter jejuni enteritis (30%), Cytomegalovirus, Epstein-Barr virus, or Zika virus. Lipooligosaccharides on the bacterial/viral cell wall share structural homology with human peripheral nerve gangliosides (GM1, GD1a, GQ1b). This molecular mimicry cross-activates B-cell production of autoantibodies that bind axonal and Schwann cell membranes, activating complement and recruiting macrophages that strip myelin sheaths, halting saltatory nerve conduction.

GBS Clinical Variant	Autoantibody Target & Pathology	Dominant Clinical Presentation
Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)	Myelin sheath destruction throughout motor and sensory nerves (most common in North America/Europe, 85–90%)	Symmetrical ascending flaccid motor weakness starting in lower extremities and progressing cephalad over days; areflexia or severe hyporeflexia; mild distal paresthesias; autonomic instability (labile blood pressure, tachy/bradycardia).
Miller Fisher Syndrome (MFS)	Anti-GQ1b ganglioside antibodies (95% specific); cross-reacts with myelin of cranial nerves III, IV, VI and cerebellar spinocerebellar tracts	Classic triad: (1) Acute Ophthalmoplegia (extraocular muscle paralysis, bilateral ptosis), (2) Severe Ataxia (loss of proprioception out of proportion to strength), and (3) Generalized Areflexia.
Acute Motor Axonal Neuropathy (AMAN)	Anti-GM1 and Anti-GD1a antibodies targeting nodes of Ranvier on axonal membranes; pure motor without sensory involvement	Rapidly progressive, severe quadriplegia and early respiratory failure; common in East Asia and South America; slower recovery.

2. Neuromuscular Respiratory Failure & The 20/30/40 Rule

Diaphragmatic and intercostal muscle paralysis develops in 25% to 30% of GBS patients, requiring mechanical ventilation. Standard pulse oximetry ($SpO_2$) remains falsely normal until catastrophic sudden respiratory arrest occurs. Bedside spirometry and pulmonary mechanics must be monitored every 2 to 4 hours:

Pulmonary Parameter	Normal Adult Value	Critical Intubation Threshold ('20/30/40 Rule')
Forced Vital Capacity (FVC)	$> 60\text{ to }70\text{ mL/kg}$	$< 20\text{ mL/kg}$ (or drop by $> 30\%$ in 24h) indicates impending diaphragmatic fatigue.
Negative Inspiratory Force (NIF)	$< -70\text{ to }-100\text{ cmH}_2\text{O}$	Less negative than -30 cmH2O (e.g., -20 to 0 cmH2O) indicates profound inspiratory muscle weakness.
Maximum Expiratory Pressure (MEP)	$> 100\text{ to }140\text{ cmH}_2\text{O}$	$< 40\text{ cmH}_2\text{O}$ indicates inability to clear bronchial secretions or cough effectively.

Critical Pitfall / Contraindication

SUCCINYLCHOLINE INDUCES FATAL HYPERKALEMIA IN GBS: The extensive motor axonal denervation in Guillain-Barré Syndrome triggers massive upregulation and proliferation of embryonic immature acetylcholine receptors (alpha-7 subunits) across the entire surface of skeletal muscle membranes. Administering succinylcholine for intubation causes prolonged, simultaneous opening of millions of these receptors, triggering a massive, uncontrolled efflux of intracellular potassium into the circulation. Serum potassium spikes by 3.0 to 6.0 mEq/L within 2 minutes, causing immediate refractory asystole and death. Always use Rocuronium (1.2 mg/kg IV) for neuromuscular blockade in GBS.

Board & Shelf Drill 5 Questions • Untimed Tutor Mode

Test Your Guillain-Barré Syndrome & Variants Clinical Acumen

Directly launch an active-recall practice block from our 8,400+ validated COMLEX Level 1, 2-CE & 3 board question bank with complete explanations.

Related Emergency Protocols & Differentials

Related EM Protocol